The Rising Price of Naloxone — Risks to Efforts to Stem Overdose Deaths
- 8 December 2016
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 375 (23), 2213-2215
- https://doi.org/10.1056/nejmp1609578
Abstract
The Food and Drug Administration (FDA) first approved naloxone in 1971 as an injection (Narcan) for reversing opioid intoxication or overdose. Although the brand-name version has been discontinued, generic versions of naloxone have been available since 1985, and today injections are available in two doses (0.4 mg per milliliter and 1 mg per milliliter; see table ). In 2014, the FDA fast-tracked approval of the first auto-injector formulation (Evzio), a fixed-dose single injection designed to allow people without medical training to reverse opioid overdose. In 2015, the agency fast-tracked approval of the first nasal-spray formulation (also marketed as Narcan); previously, naloxone injections (larger vials of a 1-mg-per-milliliter dose) had routinely been used off-label with an atomizer for nasal delivery.Keywords
This publication has 3 references indexed in Scilit:
- The High Cost of Prescription Drugs in the United StatesJama-Journal Of The American Medical Association, 2016
- ‘Government Patent Use’: A Legal Approach To Reducing Drug SpendingHealth Affairs, 2016
- Prevention of Fatal Opioid OverdoseJAMA, 2012